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STEROID REGULATION OF T CELL FUNCTION IN BPD FISCHER ET AL. 
STEROID REGULATION OF T CELL FUNCTION 
APPEARS UNALTERED IN BORDERLINE 
PERSONALITY DISORDER  
Anja Fischer, PhD, Johanna Grundmann, MSc, Stefan M. Gold, PhD, 
Carsten Spitzer, MD, and Katja Wingenfeld, PhD  
Borderline personality disorder (BPD) is characterized by instability of interpersonal 
relationships and affection, impulsivity, and cognitive disrup- tions. Increasing evidence 
suggests hypothalamic-pituitary-adrenal (HPA) axis alterations in BPD. Changed 
glucocorticoid sensitivity of peripheral blood mononuclear cells is known in mood and 
posttraumatic stress disor- ders, representing frequent comorbidities in BPD. However, to 
the authors’ knowledge, in BPD glucocorticoid sensitivity at the receptor level remains 
unexplored. Sixteen age-matched female BPD patients were compared to sixteen female 
healthy controls. In vitro steroid sensitivity of T cell prolif- eration was tested using 
aldosterone, dexamethasone, and hydrocortisone. Steroid sensitivity of BPD patients and 
healthy controls appeared compara- ble. Psychiatric comorbidities such as major 
depressive disorder or posttrau- matic stress disorder and early life stress seemed to have 
had no in uence on steroid sensitivity parameters. The data suggest unaltered GC 
sensitivity of T cell function in BPD.  
Borderline personality disorder (BPD) is characterized by instability of inter- 
personal relationships and affection as well as cognitive disruptions and im- 
pulsivity beginning in early adulthood. It frequently co-occurs with posttrau- 
matic stress disorder (PTSD) and mood disorders, which are characterized by 
altered stress-response systems such as the hypothalamic-pituitary-adrenal  
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 (HPA) axis (Wingenfeld, Spitzer, Rullkotter, & Löwe, 2010). Enhanced basal 
cortisol concentrations and reduced feedback sensitivity have been frequent- ly 
but inconsistently reported in BPD. Carvalho Fernando and colleagues (2012) 
have found evidence for HPA axis involvement in the pathogenesis of BPD, 
suggesting neuroendocrine similarities to major depressive disor- der (MDD) by 
means of increased basal cortisol concentrations. But impor- tantly, despite 
elevated cortisol levels in the dexamethasone suppression test (DST), the 
hypothesized decrease in glucocorticoid (GC) feedback inhibition was not con 
rmed. Abnormalities in HPA axis challenge tests (such as the Dex-CRH 
suppression test) or altered circadian cortisol levels are frequently interpreted as 
indicators of dysfunction at the receptor level (i.e., glucocorti- coid receptor 
[GR] or mineralocorticoid receptor [MR]). However, the mul- tiple systems 
involved in the complex regulatory feedback loop of the HPA axis complicate 
the interpretation in terms of receptor function. Intriguingly, human 
lymphocytes express mineralocorticoid and glucocorticoid recep- tors 
(Armanini, Endres, Kuhnle, & Weber, 1988) while the immune system is a 
major target of endogenous glucocorticoids (Baschant & Tuckermann, 2010). 
Thus, immune cells can be used to directly examine steroid receptor function ex 
vivo. This approach has been used to study glucocorticoid sensi- tivity in 
psychiatric disorders and thus far increased as well as decreased sen- sitivity has 
been observed (Pariante, 2004; Rohleder, Wolf, & Wolf, 2010).  
To our knowledge, studies of GC sensitivity in the immune system in the 
context of BPD have not yet been conducted. Therefore, we investigated ste- 
roid sensitivity of T cell responses as a potential biological substrate of BPD.  
METHODS  
SUBJECTS  
Age- and education-matched female patients with BPD (n = 16) and healthy 
female control subjects (HC; n = 16) were recruited from the Department of 
Psychosomatic Medicine and Psychotherapy, Schön Klinik Hamburg Eilbek, or 
via local advertisement (posters at the University Hospital and via the 
Department home page) and received nancial remuneration. All subjects 
provided written informed consent. Physical health status was assessed by 
medical history and careful clinical examination by a staff physician.  
Exclusion criteria were a history of severe somatic diseases (e.g., neuro- logical 
diseases), metabolic diseases (e.g., diabetes), endocrine disorders (e.g., 
Cushing’s syndrome), immune-mediated diseases, hypertension, or current 
infections. Furthermore, pregnancy, current anorexia, current or lifetime 
schizophrenia, alcohol or drug dependence, bipolar disorder, schizoaffec- tive 
disorder, major depression with psychotic symptoms, attention–de cit/ 
hyperactivity disorder, and cognitive impairment resulted in exclusion. The 
study was approved by the Ethics Committee of the Chamber of Physicians, 
Hamburg, Germany.  
CLINICAL ASSESSMENTS  
Patients underwent structured clinical interviews administered by trained 
psychologists (J.G., K.W.) (Structured Clinical Interview for DSM Disor- ders; 
SCID; First, Spitzer, Gibbon, & Williams, 1996). Furthermore, patients 
completed German versions of the Beck Depression Inventory (BDI; Beck, 
Ward, Mendelson, Mock, & Erbaugh, 1961), the Posttraumatic Diagnostic Scale 
(PDS; Foa, 1995), and the Borderline Symptom List (BSL; Bohus et al., 2007). 
To screen for childhood maltreatment, the German Childhood Trau- ma 
Questionnaire (CTQ; Klinitzke, Romppel, Häuser, Brähler, & Glaesmer, 2012) 
was administered.  
STEROID SENSITIVITY ASSAY  
All blood samples were taken between 8:30 and 9:30 a.m. and processed 
immediately for cryopreservation. Samples were processed according to 
standard operating procedures of the biobank of the Institute for Neuroim- 
munology and Clinical Multiple Sclerosis Research (Inims). Peripheral blood 
mononuclear cells (PBMCs) were isolated using the Ficoll-Hypague method 
and cryopreserved until assayed. After density centrifugation, PBMCs were 
resuspended in a stepwise procedure in medium 1 (RPMI-1640 + 10% FCS) and 
medium 2 (40% RPMI-1640, 40% FCS, 20% DMSO) at a concentra- tion of 107 
viable PBMCs per aliquot (1 mL) and then slowly frozen at an optimal cooling 
rate of −1°C/minute using Mr. Frosty® freezing containers (ThermoFisher 
Scienti c, Waltham, MA). After overnight cooling, aliquots were moved to an 
N2 storage facility (−180°C). Using this procedure, vi- ability of cells as 
determined by tryphan blue staining is > 95% for storage times of up to 5 years. 
For the current study, maximum storage time was 7 months. Samples from BPD 
patients and HC were run in parallel using the same batch of reagents. 
Functional steroid sensitivity of T cell function was assessed as previously 
described (Fischer et al., 2012). Cells were seeded at 2 × 106 viable cells/mL in 
RPMI-1640 (PAA Laboratories, Pasching, Austria) supplemented with 2 mM L-
glutamine and penicillin/streptomycin and stim- ulated with phytohemagglutinin 
(PHA) at a concentration of 1 μg/mL alone or in combination with one of seven 
concentrations of the agonists dexa- methasone (10–12 M to 10–6 M), aldosterone, 
or hydrocortisone (each 10–11 M to 10–5 M). PBMCs were incubated (37°C, 5% 
CO
2
) for 48 hours and then pulsed with 1 μCi/well [methyl-3H]thymidine. After 
another 24 hours, cells were harvested with a Tomtec Harvester 96® Mach III 
M (Tomtec, Inc., Hamden, CT), and thymidine incorporation was determined by 
liquid scin- tillation (Wallac 1450 microbeta, Trilux, PerkinElmer, Rodgau, 
Germany). Results were averaged from triplicate wells for each condition 
expressed as counts per minute (cpm).  
STATISTICAL ANALYSIS  
The inhibitory concentration 50 (IC-50) values representing concentrations 
inhibiting 50% of the PHA-induced proliferation for each subject and ago-  
TABLE 1. Clinical Characteristics as well as Inhibitory Concentration (IC-) 50 for Dexamethasone 
(DEX), Aldosterone (Aldo), and Hydrocortisone (Cort) of Borderline Personality Disorder (BPD)  
Patients and Matched Healthy Controls (HC)  
   
 
Age  Body height (cm)  Weight (kg)  Smoking (daily consumption) MDD (y/n)  BDI score  PTSD (y/n)  PDS 
score  Childhood trauma score  
IC-50 Dex [log M]  
IC-50 Aldo [log M]  
IC-50 Cort [log M]  
BPD (n = 16)  
26.13 + 1.12 170.31 + 1.60 62.84 + 3.16 10.97 + 1.84 08/16 21.85 + 2.84 06/16 21.8 + 3.99 59.08 + 5.18 (n = 16) −8.74 + 0.12 
−6.30 + 0.1 −7.24 + 0.12  
HC (n = 16)  
25.81 + 1.23 169.31 + 1.81 69.25 + 3.47 6.19 + 1.62 0/16 6.03 + 1.62 0/16 7.27 + 2.92 38.00 + 2.97 (n = 16) −8.71 + 0.12 −6.2 + 
0.08 7.34 + 0.14  
p value  
.72 .52 .14 .06  
.00  
.02 < .01  
p value d .89 0.06 .42 0.03 .59 0.02  
     
Note. Data are presented as mean + standard error of mean (SEM); BDI = Beck Depression Inventory, MDD = major depressive 
disorder, PTSD = posttraumatic stress disorder score, yes/no, PDS = Posttraumatic Stress Diagnotic Scale.  
nist were determined by nonlinear sigmoidal curve tting utilizing Prism® 
Software as described by Fischer et al. (2012). All variables were tested for 
normality and equality of variance. Student t tests were conducted in order to 
detect differences between the BPD and healthy control (HC) groups us- ing 
PASW Statistics 18 software, with p values < 0.05 considered signi cant.  
RESULTS  
Patients with BDP and HC were well matched for age, body height, and weight, 
while there was a marginally signi cant difference for smoking (Ta- ble 1). In 
the patient group, patients met, on average, six of the DSM-IV cri- teria for 
BPD. In addition, eight BPD patients met DSM-IV criteria for MDD and six 
were diagnosed with PTSD (Table 1). Four of these BPD patients had both 
comorbidities. While seven of the BDP patients were untreated, several 
participants in the patient group were taking psychotropic medication. These 
included atypical antipsychotics (Quentiapine, n = 4; Olanzapine, n = 1) as well 
as antidepressive treatment (noradrenergic and speci c serotonergic an- 
tidepressants, n
Mirtazapine 
= 1; Selective serotonin reuptake inhibitors, n
Citalopram 
= 2, 
n
Fluoxetine 
= 1; tricyclic antidepressants, n
Trimipramine 
= 1; serotonin and nor- 
epinephrine reuptake inhibitors, n
Venlafaxine 
= 1). HC were free of psychiatric 
disorders according to SCID.  
As expected, BPD patients had signi cantly higher scores on self-report 
measures of depression (BDI), childhood trauma (CTQ), and PTSD (PDS) 
compared to HC. There were no signi cant differences between BPD and HC in 
T cell steroid sensitivity as measured by IC-50 values with any of the three 
agonists (see Table 1 and Figure 1). Exploratory analyses revealed  
 FIGURE 1. Steroid sensitivity in borderline personality disorder and healthy controls. Relative 
proliferation (counts per minute [cpm]/ PHA control) in the presence of PHA (present in all 
conditions) and different concentrations of (a) dexamethasone (Dex) (b) aldosterone (Aldo), and 
(c) hydrocortisone (Cort) both in individuals with Border- line personality disorder (BPD) and in 
healthy controls (HC).  
no correlations between IC-50 values and measures of BPD symptoms as 
measured by the BSL (pdex = .68, paldo = .32, pCort = .99), depression severity as 
indicated by BDI scores (pdex = .79, paldo = .38, pCort = .94), the occurrence of 
childhood trauma according to the CTQ score (pdex = .32, paldo = .77, pCort = .93), 
or PTSD symptoms (PDS score, pdex = .48, paldo = .68, pCort = .85).  
DISCUSSION  
To our knowledge, this is the rst study assessing steroid sensitivity in the 
immune system in the context of BPD. Our results indicate no apparent al- 
terations in T cell steroid sensitivity in BPD. As expected, MDD and PTSD 
comorbidity was frequent in the patient group. However, GC sensitivity was not 
associated with depressive symptoms, PTSD severity, or early life stress (ELS). 
The cortisol suppression capacity in the DST is considered a mea- sure of the 
HPA axis GR-mediated negative feedback function. HPA axis 
hyporesponsiveness with lower basal cortisol levels and pronounced cortisol 
suppression in the DST have also been reported in BPD, but the majority of 
studies support the notion of a hyperreactive HPA system (Carvalho Fer- nando 
et al., 2012). Furthermore, HPA hyperresponsiveness as measured by the Dex-
CRH test was found in BPD patients with a history of chronic abuse in early 
childhood (Rinne et al., 2002). The authors hypothesized that ELS accounts for 
this altered HPA state in BPD. Importantly, Carvalho Fernando et al. (2012) 
have found increased cortisol levels in the DST in BPD, as well as an 
association between cortisol release and childhood trauma. In contrast to basal 
and stimulated cortisol (i.e., regulation of the HPA axis itself), we did not nd 
evidence for an association between childhood trauma and GC sensitivity in 
peripheral immune cells (i.e., a major target tissue of endog- enous 
glucocorticoids). Our data suggest that GC sensitivity of T cell func- tion is 
unaltered in BDP, which may indicate a tissue-speci c dysregulation of steroid 
signaling. In vitro inhibition of cell proliferation has previously been used to 
reveal differences in GC sensitivity of T cells as a biological substrate of 
depressive symptoms in patients with multiple sclerosis, a neuro- in ammtory 
disease of presumably T cell–driven origin (Fischer et al., 2012). Similarly, 
studies have shown altered GC sensitivity of T cell proliferation in patients with 
PTSD (de Kloet et al., 2007) and major depression (Lowy, Reder, Gormley, & 
Meltzer, 1988; Wodarz et al., 1991). This would suggest that the assay system is 
speci c and sensitive to pick up GC sensitivity differ- ences in T cell function in 
autoimmune and psychiatric disorders, but that T cell regulation by GCs is 
unaltered in BPD. However, our results do not rule out the possibility that other 
immune cell subpopulations of the innate (e.g., monocytes, NK cells) or 
adaptive immune system (e.g., B cells) may show al- tered GC regulation in 
BPD. This remains to be elucidated with appropriate functional assay systems.  
BPD is a very heterogeneous disorder, and it becomes increasingly clear that 
comorbidities and clinical features such as trauma history may have variable, 
interacting in uences on the neuroendocrine pro le in BPD (Zim- merman & 
Choi-Kain, 2009). However, GC sensitivity measures were not correlated to 
severity of depression, severity of PTSD symptoms, or CTQ scores in our study. 
It has been previously reported that elevated free cor- tisol levels in BPD 
patients are positively correlated to MDD severity and negatively associated 
with PTSD symptomatology (Wingenfeld, Driessen, Adam, & Hill, 2007). In a 
longitudinal study, DST results were identi ed as a stable marker of abnormal 
HPA axis function in BPD with comorbid PTSD, resulting in more pronounced 
suppression (Wingenfeld, Lange, et al., 2007). In another study, it was shown 
that acute hydrocortisone administra- tion had bene cial effects on 
hippocampus-relevant memory in BPD, while in healthy controls 
hydrocortisone impaired memory retrieval (Wingenfeld et al., 2013). These 
results were interpreted in terms of a cortisol-induced enhancement of 
hippocampal functioning, which might be related to a sen- sitization of GR 
function. Possibly, in BPD, altered GR function might be more tissue speci c 
and restricted to CNS GR (e.g., in the hippocampus and hypothalamus) as well 
as the pituitary.  
The present study has several limitations. Due to the small sample size, lack of 
power is obviously an issue, and the absence of statistically signi cant 
differences could re ect this fact rather than absence of a biological effect. 
Therefore, we have also provided effect sizes, which were all well below the 
accepted thresholds for small effects (Table 1). In addition, the overlapping 
steroid sensitivity curves and the small error bars observed (Figure 1) argue 
against a biologically signi cant effect. Given these considerations and the very 
low effect sizes obtained in this pilot study, we believe that BPD is un- likely to 
be linked to altered steroid sensitivity of T cell responses. In addi- tion, in this 
small pilot study, we did not obtain measures of GC regulation in other systems, 
most notably in the HPA axis itself. Therefore, future studies should assess HPA 
axis regulation (such as the Dex-CRH test) in parallel with functional assays of 
GC sensitivity in important target tissues of endog- enous cortisol, such as cells 
of the innate and adaptive immune system.  
In conclusion, our study suggests unaltered GC sensitivity in T cells in BPD, a 
major compartment of the adaptive immune system.  
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